Copeland Capital Management LLC Trims Position in LeMaitre Vascular, Inc. $LMAT

Copeland Capital Management LLC decreased its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 2.1% during the 1st quarter, HoldingsChannel.com reports. The firm owned 870,692 shares of the medical instruments supplier’s stock after selling 18,285 shares during the period. LeMaitre Vascular accounts for approximately 2.1% of Copeland Capital Management LLC’s investment portfolio, making the stock its 3rd biggest holding. Copeland Capital Management LLC’s holdings in LeMaitre Vascular were worth $95,054,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Illinois Municipal Retirement Fund increased its position in shares of LeMaitre Vascular by 1.1% during the fourth quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock worth $906,000 after buying an additional 123 shares during the period. NewEdge Advisors LLC lifted its stake in shares of LeMaitre Vascular by 4.6% in the fourth quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock valued at $256,000 after buying an additional 139 shares in the last quarter. State of Alaska Department of Revenue boosted its stake in LeMaitre Vascular by 1.2% during the 4th quarter. State of Alaska Department of Revenue now owns 11,986 shares of the medical instruments supplier’s stock valued at $971,000 after purchasing an additional 147 shares during the last quarter. Federated Hermes Inc. boosted its position in shares of LeMaitre Vascular by 0.4% during the second quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock valued at $3,294,000 after buying an additional 155 shares during the last quarter. Finally, Pictet Asset Management Holding SA boosted its holdings in LeMaitre Vascular by 5.5% during the 1st quarter. Pictet Asset Management Holding SA now owns 3,259 shares of the medical instruments supplier’s stock worth $356,000 after acquiring an additional 169 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Stock Performance

NASDAQ LMAT opened at $101.63 on Friday. The company has a market capitalization of $2.32 billion, a PE ratio of 37.50, a price-to-earnings-growth ratio of 2.86 and a beta of 0.52. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32. LeMaitre Vascular, Inc. has a 52-week low of $79.00 and a 52-week high of $118.01. The company has a 50-day simple moving average of $97.00 and a 200 day simple moving average of $98.42.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02. The firm had revenue of $66.55 million during the quarter, compared to the consensus estimate of $66.67 million. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The company’s revenue was up 11.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.48 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. On average, research analysts predict that LeMaitre Vascular, Inc. will post 3 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Thursday, May 21st were paid a $0.25 dividend. The ex-dividend date was Thursday, May 21st. This represents a $1.00 annualized dividend and a dividend yield of 1.0%. LeMaitre Vascular’s payout ratio is presently 36.90%.

Insider Activity

In other news, CEO George W. Lemaitre sold 27,881 shares of the company’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $108.69, for a total transaction of $3,030,385.89. Following the transaction, the chief executive officer owned 1,430,019 shares of the company’s stock, valued at $155,428,765.11. This represents a 1.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bridget A. Ross sold 5,044 shares of LeMaitre Vascular stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $111.10, for a total value of $560,388.40. Following the completion of the sale, the director directly owned 3,942 shares of the company’s stock, valued at approximately $437,956.20. This trade represents a 56.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 54,453 shares of company stock valued at $5,906,174 in the last 90 days. Insiders own 7.40% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on LMAT shares. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday, July 4th. Weiss Ratings downgraded LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, June 30th. Freedom Capital raised LeMaitre Vascular to a “hold” rating in a report on Tuesday, March 31st. Barrington Research reaffirmed an “outperform” rating and set a $120.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, June 3rd. Finally, Citizens Jmp lifted their price target on LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 6th. Four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, LeMaitre Vascular has a consensus rating of “Moderate Buy” and a consensus target price of $112.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.